Such tumors, when treated with monoclonal antibody targeting the epidermal growth factor receptor (EGFR), will eventually develop resistance to anti-EGFR therapy, a characteristic most prominent in colorectal cancer [17,18]. This evidence concerns the gene EGFR and colorectal cancer.